SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

OPTUNE

ZLAB·Zai Lab Ltd
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (marketed device)
Time to market
Already marketed in China for GBM. The pancreatic cancer indication is under NMPA review (Innovative Medical Device Designation granted August 2025; submission planned H2 2025), with no confirmed approval date yet.
Why 4/10
OPTUNE is already approved and commercialized in China for GBM with no pending binary regulatory decision for that indication. The next potential catalyst is NMPA approval for pancreatic cancer, but no confirmed PDUFA or decision date exists as of November 2026. The drug is one of many products in Zai Lab's portfolio and its revenue is declining due to competition. Per the rubric, an approved marketed drug with no imminent new regulatory decision scores 3-5.
Actionable Insight NEUTRAL

Watch for NMPA acceptance and a potential approval decision for OPTUNE in pancreatic cancer, which would open a large new addressable market in China. However, the lack of a confirmed submission or decision date as of Q3 2026 earnings means this catalyst is not imminent. Monitor quarterly revenue trends for Optune in GBM, as competition is eroding market share. Zai Lab's next major near-term catalyst is the November 30, 2026 PDUFA date for povetacicept in IgA nephropathy, a separate pipeline asset.

Price Chart

Loading chart...

Executive Summary

OPTUNE (Tumor Treating Fields / TTFields) is a wearable medical device that uses electric fields to disrupt cancer cell division, developed by Novocure (NVCR) and exclusively licensed to Zai Lab (ZLAB) for Greater China. It is already approved and marketed in China for glioblastoma (GBM) since May 2020. Zai Lab is pursuing NMPA approval for a second indication in pancreatic cancer, having received Innovative Medical Device Designation in August 2025 based on positive Phase 3 PANOVA-3 data. However, Optune revenue is declining due to increasing competition in the GBM market, and the pancreatic cancer regulatory timeline remains unconfirmed. Optune is one of many products in Zai Lab's diversified portfolio, which includes ZEJULA, NUZYRA, VYVGART, KarXT, and a pipeline centered on the zoci ADC program.

How It Works

OPTUNE is a wearable, portable medical device that delivers low-intensity alternating electric fields (called Tumor Treating Fields or TTFields) through adhesive patches placed on the skin. These electric fields physically disrupt cancer cell division and can kill cancer cells without the systemic side effects of chemotherapy. It is not a drug or radiation therapy; it is a non-invasive physical treatment the patient wears for most of the day.

Trial Status

OPTUNE is already approved and marketed in China (NMPA approval May 2020) for newly diagnosed glioblastoma (GBM) in combination with temozolomide and as a monotherapy for recurrent GBM. It is also FDA-approved in the US for GBM and, since February 2026, for locally advanced pancreatic cancer (as Optune Pax). In China, Zai Lab received Innovative Medical Device Designation from the NMPA in August 2025 for the pancreatic cancer indication based on positive Phase 3 PANOVA-3 data, with a regulatory submission planned for the second half of 2025. The Phase 3 METIS trial also showed TTFields significantly delayed intracranial progression in NSCLC patients with brain metastases.

The Two-Sided Case

▲ Bull Case3
OPTUNE is a novel, non-invasive physical cancer therapy with a differentiated mechanism that avoids systemic toxicity, already approved in China for GBM and in the US for GBM and pancreatic cancer.
The pancreatic cancer opportunity in China is large: approximately 134,000 new cases annually with a five-year survival rate under 10%, and the Phase 3 PANOVA-3 trial showed a statistically significant overall survival improvement (16.2 vs 14.2 months).
Zai Lab has an exclusive license for Greater China from Novocure, and the NMPA granted Innovative Medical Device Designation for the pancreatic cancer indication, which can expedite regulatory review.
▼ Bear Case4
OPTUNE revenue is declining in China due to evolving competition in the glioblastoma market, as noted in Zai Lab's Q3 2026 earnings (November 5, 2026).
The device-based therapy requires patients to wear the device most of the day, which may limit adoption versus oral or infusion-based cancer treatments.
The pancreatic cancer NMPA submission timeline is uncertain (planned H2 2025 but no confirmed filing or approval date as of November 2026), and the addressable market for a wearable device in pancreatic cancer is unproven in China.
OPTUNE is just one of many products in Zai Lab's portfolio; the company's pipeline focus is shifting toward internal assets like zoci (DLL3 ADC), and Optune's contribution to overall revenue is declining.

Upcoming Catalysts

  • Potential NMPA approval decision for OPTUNE in pancreatic cancer (submission planned H2 2025, no confirmed date yet)
  • Expansion of TTFields into additional solid tumor indications (NSCLC brain metastases via METIS trial data)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Zai Lab Ltd 8-K ZLAB ·Originating report

Sources · 9

Hover a chip for the title
1 zailaboratory.com2 businesswire.com3 flcube.com4 flcube.com5 flcube.com6 biospace.com7 stocktitan.net8 flcube.com9 fool.com